Source from Kelvin A. Power’s Facebook on July 31, 2019
အမှန်တရားကိုပြောရရင်တကယ်တော့ဒီကမ္ဘာပေါ်မှာဆီးချိုသွေးချိုရောဂါဆိုတာလုံးဝကိုမရှိပါဘူး။ဒီလိုမရှိတဲ့ရောဂါတွေကိုရှိတယ်ထင်ပြီးထိုင်ကုနေရင်တော့တသက်လုံးမပျောက်ပါဘူး။ပိုမိုရှုပ်ထွေးလာပြီးအသက်ဆုံးရှုံးကြရတာပါပဲ။
———
ဒီခေတ်ဆေးပညာရှင်တွေ၊ဆရာဝန်တွေကမရှိတဲ့ဆီးချိုရောဂါဆိုတာကြီးကိုရှိတယ်ထင်ပြီးတော့(၃)မျိုးလောက်ခွဲခြားသတ်မှတ်ပေးထားပါတယ်။အဲဒါတွေကတော့Type-1, Type-2, Type-3 ပါ။
ဒီရောဂါတွေအားလုံးမှာတူညီနေတဲ့သွေးထဲမှာသကြားဓါတ်များတဲ့လက္ခဏာလေးတခုကိုကြည့်ပြီးတော့ဆီးချိုသွေးချိုရောဂါ(Diabetes)လို့အတူတူခေါ်ဆိုလိုက်ကြတာပါ။တကယ်တော့ဒီကမ္ဘာပေါ်မှာဆီးချိုသွေးချိုရောဂါဆိုတာရှိကိုမရှိပါဘူး။ဆီးချိုသွေးချိုတယ်ဆိုတာကရောဂါမဟုတ်ပါဘူး၊အောက်ခံဖြစ်နေတဲ့ရောဂါတခုခုကပြနေတဲ့လက္ခဏာသက်သက်ပါ။ဒီရောဂါတွေကိုဆီးချိုရောဂါလို့ထင်ပြီးကုသနေရင်တသက်လုံးမပျောက်ပါဘူး။ဒီရောဂါတွေမဖြစ်အောင်လဲမကာကွယ်နိုင်ပါဘူး။ဒီနေရာမှာသေချာပြတ်ပြတ်သားသားရှင်းရှင်းလင်းလင်းသိဖို့လိုအပ်နေပါပြီ။ဆီးချိုတယ်သွေးချိုတယ်ဆိုတာကအောက်ခံရောဂါတခုခုရှိလို့ဖြစ်လာတယ့်လက္ခဏာ(symptoms)တွေပါ။ခန္ဒာကိုယ်ဆိုတာအောက်ခံရောဂါတခုခုဖြစ်နေရင်လက္ခဏာပြတာသဘာဝပါပဲ။လက္ခဏာ(symptoms)ဆိုတာနောက်ခံအကြောင်းတရား(cause)အစစ်မဟုတ်ပါဘူး၊တခြားအကြောင်းတရားတွေကြောင့်ဖြစ်လာရတဲ့အကျိုးတရားသက်သက်ပါ။ဒီနေရာမှာသိပ်အဓိပ္ပါယ်လေးနက်တဲ့စကားနဲ့ပြောနေတာပါ။သဘောမပေါက်ရင်နစ်ခေါက်သုံးခေါက်လောက်သေချာပြန်ဖတ်ပါ။
———-
ရှင်းသွားအောင်ထပ်ပြောပါဦးမယ်။ဖြစ်နေတဲ့ရောဂါနဲ့၊ရောဂါကပြတဲ့လက္ခဏာဆိုတာလုံးဝကိုမတူပါဘူး၊တခြားစီပါ။ရောဂါနဲ့၊လက္ခဏာကိုကွဲကွဲပြားပြားအရင်သိဖို့လိုအပ်ပါတယ်။ကျွန်တော်ကရောဂါကြောင့်ဖြစ်လာတဲ့လက္ခဏာကိုကုတဲ့နည်းအပင်ပန်းခံပြီးမရေးပါဘူး။အောက်ခံမူရင်းဇစ်မြစ်ဖြစ်နေတဲ့ရောဂါကုသနည်းကိုပဲရေးပေးမှာပါ။ဆီးချိုတယ်ဆိုတဲ့လက္ခဏာကိုကျွန်တော်မကုပါဘူး။ကုလဲမပျောက်နိုင်ပါဘူး၊ဘာကြောင့်မပျောက်နိုင်လဲဆိုတော့လောကမှာအကျိုးတရားကိုဘယ်တော့မှပြုပြင်ပြောင်းလဲလို့မရနိုင်ပါဘူး။အကျိုးတရားဆိုတာကိုဆရာဝန်တွေမဆိုထားနဲ့မြတ်စွာဘုရားတောင်ပြုပြင်လို့မရပါဘူး။အကျိုးတရားကိုပြုပြင်ဖို့ကျိုးစားတဲ့သူဟာလူမိုက်ပါပဲ။အကျိုးတရားကိုပြောင်းလဲစေချင်ရင်အကြောင်းတရားကိုရှာပြီးပြုပြင်ပေးရပါတယ်။လောကမှာဘယ်အကြောင်းတရားကြောင့်ဘယ်အကျိုးတရားဖြစ်တယ်ဆိုတာကိုသိတဲ့သူဟာပညာရှိအစစ်ပါပဲ။ဒီနေရာမှာအားမနာတန်းပြောရရင်မိမိရောဂါဖြစ်တော့မှာဆရာဝန်တွေဆီကိုပြေးသွားပြီးကယ်ကြပါယူကြပါလုပ်နေတဲ့လူတွေဟာအကျိုးတရားကိုပြုပြင်ဖို့ကျိုးစားနေကြတဲ့လူမိုက်တွေပါ။ရောဂါတွေအကြောင်း၊အဟာရတွေအကြောင်း၊ဖြည့်စွတ်စာတွေအကြောင်း၊ရောဂါဖြစ်ပွားရတဲ့အကြာင်းတရားတွေ၊ဗဟုသုတတွေကိုသေချာလေ့လာဖတ်ရှုထားပြီး၊အဲဒီရောဂါတွေဖြစ်စေတဲ့အကြောင်းတရားတွေကိုကြိုတင်ပြီးပါယ်ဖျက်ထားတဲ့၊အဟာရပညာနဲ့ဖြည့်စွတ်စာကိုယုံကြည်ကြတဲ့လူတွေကတော့တကယ့်ပညာရှိတွေပါ။အကြောင်းတရားကိုကြိုတင်မပါယ်ဖျက်ထားပဲနဲ့အကျိုးတရားဖြစ်လာတော့ာမှဆရာဝန်တွေဆီသွားပြီးကယ်ပါယူပါသွားလုပ်မယ်ဆိုရင်တော့ဆရာဝန်မပြောပါနဲ့မြတ်စွာဘုရားတောင်မကယ်နိုင်ပါဘူး။ဒီလောက်ဆိုရှင်းပါတယ်နော်။
———
ခက်တာကဒီခေတ်ဆေးရုံဆေးခန်းတွေ၊ဆရာဝန်တွေဟာရောဂါတွေကိုကုသတဲ့အခါမှာအခြေခံအကြောင်းတရားကိုစိတ်မဝင်စားကြပါဘူး။သိလဲမသိပါဘူး။သိအောင်လဲမကျိုးစားကြပါဘူး။ဘာကြောင့်လဲဆိုတော့ဒီခေတ်ဆေးပညာဟာအကြောင်းတရားကိုရှာပြီးကုသပေးဖို့ဒီဇိုင်းလုပ်ထားတဲ့ဆေးပညာလဲမဟုတ်ပါဘူး။ဒီခေတ်ဆေးပညာကဆီးချိုရောဂါကိုဆေးတွေဘဲတိုက်တိုက်၊ဆေးဘဲထိုးထိုး၊အင်ဆူလင်ပဲထိုးထိုး၊ဘယ်လိုကွဲကွဲပြားပြားပဲကုကု၊ရည်ရွယ်ချက်ကတစ်ခုတည်းအတူတူပါပဲ။အဲဒီရည်ရွယ်ချက်ကဘာလဲဆိုတော့သွေးထဲမှာချိုနေတဲ့သကြားဓါတ်ကိုကျသွားအောင်အမျိုးမျိုးအဖုန်ဖုန်လုပ်ယူဖို့ကျိုးစားနေကြတာပါပဲ။ဆီးချိုရောဂါရဲ့လက္ခဏာဖြစ်တဲ့ဆီးချိုတယ်သွေးချိုတယ်ဆိုတဲ့လက္ခဏာ(symptoms)လေးတွေပျောက်သွားအောင်အမျိုးမျိူးလုပ်နေကြတာဟာမှန်ကန်တဲ့ကုသနည်းမဟုတ်ပါဘူး။ဆီးချိုတယ်သွေးချိုတယ်ဆိုတာအကြောင်းတရားမဟုတ်ပါဘူး။အခြားအကြောင်းတွေကြောင့်ဖြစ်နေရတဲ့အကျိုးတရားလက္ခဏာပါ။
——–
ဥပမာကောင်းကောင်းလေးတခုပေးရရင်၊ဉာဏ်ပညာနည်းတဲ့ထင်းခုတ်သမားတစ်ယောက်ဟာထင်းကိုအလိုရှိလို့တောထဲကိုဝင်သွားပြီးတော့ထင်းရှာပါတယ်။ဒီလိုနဲ့သစ်ပင်တပင်ကိုတွေ့တော့သစ်ပင်ရဲ့ပင်စည်ကိုမခုတ်လှဲပဲ၊နေရောင်ကြောင့်မြေကြီးပေါ်မှာကျနေတဲ့အဲဒီအပင်ရဲ့အရိပ်ကိုတနေကုန်ထိုင်ခုတ်နေတာနဲ့တူနေပါတယ်။ဘယ်လောက်မိုက်မဲတဲ့ထင်းခုတ်သမားလဲဆိုတာစဉ်းစားကြည့်ကြပေါ့ဗျာ။ဒီခေါတ်ဆေးပညာနဲ့ကုရင်ဆီးချိုရောဂါဘယ်တော့မှမပျောက်ပါဘူး။ကုလေပိုဆိုးလေ၊ပိုပြီးရှုပ်ထွေးလာလေ။ငွေလဲကုန်၊လူလဲဝေဒနာဆိုးအမျိုးမျိုးခံရနဲ့၊နောက်ဆုံးတော့လဲအသက်ဆုံးရှုံးကြရရှာတာပါပဲ။အမှန်အတိုင်းတည့်ပြောရရင်၊ဒီခေတ်ဆေးပညာဟာ၊နာတာရှည်ရောဂါတွေကိုပျောက်အောင်ကုသဖို့ဒီဇိုင်းလုပ်ထားတာမဟုတ်ပါဘူး။လူနာတွေဆီကပိုက်ဆံကိုမသေမချင်းညှင်းဆဲပြီးရေရှည်များများရအောင်၊ရောဂါမပျောက်ကင်းအောင်တမင်ရေရှည်ဆွဲကုဖို့အရှင်းရှင်ဆေးကုမ္မဏီကြီးတွေကိုယ်တိုင်ဒီဇိုင်းဆွဲချမှတ်ထားပေးတာပါ။အခုခေတ်မှာကျန်းမာရေးအတွက်ဆေးပညာဆိုတာမရှိတော့ပါဘူး။စီးပွါးရေးအတွက်ဆေးပညာဖြစ်သွားပါပြီ။ကိုယ်ကအဲဒီအရင်းရှင်ဆေးပညာရဲ့ဓါးစာခံသားကောင်မဖြစ်အောင်ဒီစာရေးပေးနေရတာပါ။ဒီနေရာမှာဆရာဝန်တွေကိုပုတ်ခတ်ပြီးပြောနေတာလုံးဝမဟုတ်ပါဘူး။ဘာကြောင့်လဲဆိုတော့အဲဒီဆရာဝန်တွေကိုယ်တိုင်ကကျွန်တော်တို့တွေလိုပဲတလှေထဲစီးတခရီးတည်းသွားနေရရှာတဲ့ဒီအရင်းရှင်ဆေးပညာစနစ်ရဲ့ဓါးစာခံသားကောင်တွေဖြစ်နေလို့ပါပဲ။
—————–
ဆီးချိုရောဂါအကြောင်းပြန်ဆက်ပါမယ်၊ဆီးချိုရောဂါအားလုံးဟာသွေးထဲမှာသကြားဓါတ်များနေတဲ့လက္ခဏာချင်းကတော့အတူတူပါပဲ။ဒါပေမဲ့ဘာကြောင့်သွေးထဲမှာသကြားဓတ်များတယ်ဆိုတဲ့အောက်ခံအကြောင်းတရားတွေကတော့တခြားစီပါ။Type-1 Diabetes ဆိုတာမရှိပါဘူး။Type-1 Diabetes ဆိုတာ(Autoimmune Disease)သက်သက်ကြီးပါ။မိမိခန္ဓာကိုယ်ကမိမိပန်ခရိယထဲမှာရှိနေတဲ့အင်ဆူလင်ဟော်မုန်းထုတ်ပေးတဲ့ဗေဒါဆဲလ်(Beta Cells)တွေကိုတိုက်ခိုက်ဖျက်ဆီးခံရလို့ဖြစ်လာရတာပါ။သွေးထဲမှာသကြားဓါတ်နည်းအောင်ကုပေးနေရုံနဲ့တော့ဒီရောဂါဘယ်တော့မှမပျောက်ကင်းနိုင်ပါဘူး။(Autoimmune Disease)ကုသနည်းကိုရေးတော့မှဒီ(Type-1 Diabetes)လဲအလိုလိုပါသွားမှာပါ။အခုတော့သူ့အကြောင်းအသေးစိတ်မရေးသေးပါဘူး။
—————–
Type-3 Diabetes ဆိုတာက Alzheimer’s Disease လို့လဲခေါ်ပါတယ်။(Metabolic Disease)ပါ။ခန္ဓာကိုယ်ရဲ့ဇီဝစမ်းအင်ထုတ်လုပ်ဖြန့်ဖြူးသိုလောင်မှုစနစ်မမှန်ကန်လို့ဖြစ်လာရတာပါ။သူကတော့ဦးနှောက်ထဲမှာဖြစ်တာပါ။(protein glycation)ကြောင့်(beta-amyloid formation)ဦးနောက်ထဲမှာဖြစ်လာရတာပါ။သူ့အကြောင်းလဲနောက်မှအသေးစိတ်ရေးပေးပါမယ်။
———————-
ဒီပို့စ်မှာတော့(Type-2 Diabetes)အကြောင်းကိုပဲအဓိကထားပြီးအကျယ်ရေးပေးပါမယ်လို့ရည်ရွယ်ထားပါတယ်။
Type-2 Diabetes ဆိုတာကတော့ Metabolic Disease ပါပဲ။ခန္ဒာကိုယ်ရဲ့ဇီဝစွမ်းအင်ထုတ်လုပ်ဖြန့်ဖြူးသိုလောင်မှု့စနစ်မမှန်ကန်လို့ဖြစ်လာရတာပါ။
ဒီရောဂါနဲ့ပါတ်သက်လို့လူတွေလုံးဝမသိသေးတဲ့အချက်ကတော့ဒီType-2 Diabetes ဆိုတာဆီးချိုရောဂါလုံးဝမဟုတ်ပါဘူး၊အသဲရောဂါ(Liver Disease) သက်သက်ဆိုတာပါပဲ။ ဒီအချက်ကလူတွေမသိသေးတဲ့သိပ်အရေးကြီးတဲ့အချက်ပါ။ဒီရောဂါဟာစမ်းသပ်လို့မလွယ်လောက်အောင်နုးညံ့သိမ်မွေ့လွန်းတဲ့အသဲရောဂါပါ။ဒါကြောင့်အသဲကြောင့်စဖြစ်ရတယ်ဆိုတာကိုဆရာဝန်တွေကိုယ်တိုင်တောင်မသိနားမလည်ကြသေးပါဘူး။အင်ဆူလင်လို့ခေါ်တဲ့ဟော်မုန်းဓါတ်ခုခံမှု(Insulin Resistance)ကြောင့်ဖြစ်တယ်လို့တော့လူအချို့သိထားကြပါတယ်။ဒါပေမဲ့သူတို့ထင်ထားတာကကြွက်သား (Muscle)တွေနဲ့တခြားကိုယ်အင်္ဂါအစိတ်အပိုင်းတွေမှာအင်ဆူလင်ခုခံမှုဖြစ်တယ်လို့ထင်ကြပါတယ်။ဒါပေမဲ့မဟုတ်ပါဘူး။တခြားကိုယ်အင်္ဂါအစိတ်အပိုင်းတွေမှာအင်ဆူလင်ခုခံမှုဖြစ်လာရင်ဝလာပါတယ်၊ဆီးချိုမဖြစ်လာပါဘူး။လက်တွေ့မှာကအင်ဆူလင်ခုခံမှုဖြစ်တာခြင်းအတူတူတချို့ကဝလာပါတယ်၊ဝပေမဲ့လဲဆီးချိုမဖြစ်ပါဘူး၊တချို့ကြတော့ပိန်ပါတယ်၊ပိန်ပေမဲ့လဲဆီးချိုဖြစ်လာတတ်ပါတယ်။ဒီအဖြေကရှင်းပါတယ်။တကယ်တော့အသဲ(Liver)မှာအင်ဆူလင်ခုခံမှုဖြစ်မှသာလျှင်(Type-2 Diabetes)ဖြစ်လာရတာပါ။တခြားကိုယ်အင်္ဂါအစိတ်အပိုင်းတွေမှာအင်ဆူလင်ခုခံမှုဖြစ်ပြီးအသဲကောင်းနေသေးရင်ဝသာဝလာပြီးဆီးချိုရောဂါမဖြစ်လာနိုင်သလို။တခြားကိုယ်အင်္ဂါအစိတ်အပိုင်းတွေမှာအင်ဆူလင်ခုခံမှုမရှိပဲအသဲမှာခုခံမှုရှိလာရင်ပိန်နေပြီးတော့လဲဆီးချိုရောဂါရလာတတ်ပါတယ်။ဝလဲဝဆီးချိုလဲဖြစ်တယ်ဆိုရင်တော့အသဲမှာရောတခြားကိုယ်အင်္ဂါအစိတ်အပိုင်းတွေမှာရောအင်ဆူလင်ခုခံမှုဖြစ်နေလို့ပါ။
——————
ဆီးချိုသွေးချိုဆိုတာရောဂါမဟုတ်ပဲလက္ခဏာတွေသာဖြစ်နေလို့ကျွန်တော်ဆီးမချိုအောင်သွေးမချိုအောင်ဘယ်လိုလုပ်ရမယ်လို့အချိန်ကုန်ခံပြီးမပြောတော့ပဲအသဲကိုအခြေခံတဲ့ရောဂါဖြစ်နေလို့အသဲကိုကုသနည်းကိုပဲသင်ပေးသွားမှာပါ။သွေးထဲမှာသကြားဓါတ်လေးလျှော့သွားအောင်ဦးတည်ကုနေလို့ကတော့တသက်လုံးမပျောက်နိုင်ပါဘူး။ပိုပိုရှုပ်ထွေးလာပြီးအသက်အန္တရာယ်ကိုပါထိခိုက်လာနိုင်ပါတယ်။အဓိကပြစ်မှတ်ထားကုရမှာကသွေးထဲကသကြားဓါတ်နည်းသွားစေဖို့မဟုတ်ပါဘူး။အသဲရဲ့ဇီဝစွမ်းအင်ထုတ်လုပ်ဖြန့်ဖြူးသိုလောင်မှုစနစ်(liver metabolism)တွေမှန်ကန်လာဖို့ကုသရမှာပါ။ဒီလိုကုသတော့မှဒီရောဂါကိုအမြစ်ပြတ်ပျောက်ကင်းနိုင်မှာပါ။ဒီလိုမှမကုသပဲမနက်လင်းလာတာနဲ့ဆရာဝန်တွေသင်ထားပေးတဲ့အတိုင်းအစာမစားခင်လေးသွေးထဲမှာသကြားဓါတ်တိုင်းကြည့်၊သကြားဓါတ်တက်လာရင်ဆရာဝန်ပေးထားတဲ့ဆေးတွေသောက်၊အင်ဆူလင်တွေထိုးထည့်ပြီးသကြားဓါတ်လျှော့နည်းသွားအောင်ထိုင်လုပ်နေရုံနဲ့ကတော့ခဏပါပဲရေရှည်မှာတော့ဘယ်တော့မှမသက်သာလာပဘဲပိုပိုပြီဆိုးလာပါလိမ့်မယ်။ဘာနဲ့တူနေလဲဆိုတော့အရက်သောက်များလို့အရက်နာကျနေတဲ့လူကိုအရက်ထပ်တိုက်ပြီးပြန်ဖြေပေးနေရသလိုပါပဲ။ရောဂါအရင်းအမြစ်ကိုမကုသပဲအပေါ်ယံလက္ခဏာဖြစ်တဲ့သွေးထဲကသကြားဓါတ်လျှော့သွားရေးကိုသာထိုင်ပြီးကုသနေရင်တော့စောစောကပြောထားတဲ့ဥပမာလေးအတိုင်း၊သစ်ပင်ကိုမခုတ်ပဲ၊သစ်ပင်ရဲ့အရိပ်ကိုသာထိုင်ခုတ်နေတဲ့အလွန်မိုက်မဲတဲ့ထင်းခုတ်သမားတစ်ယောက်နဲ့တူနေပြီဆိုတာသတိထားမိစေချင်ပါတယ်။
————–
(Type-2 Diabetes)ဆိုတာဘယ်လိုအကြောင်းတရားကြောင့်၊ဘယ်ကနေဘယ်လိုအသဲထဲမှာအခြေတည်ပြီးစဖြစ်လာတယ်ဆိုတဲ့လူတွေမသိသေးတဲ့အကြောင်းတွေကိုအကြောင်းအကျိုးဆက်စပ်ပြီးအသေးစိတ်နောက်မှသေချာရေးပေးပါမယ်။ဒီလိုဖြစ်လာရတဲ့အကြောင်းတရားဇစ်မြစ်ကိုသေသေချာချာနားလည်ပြီးတော့မှ၊ဘယ်လိုကုသလိုက်ရင်အလွယ်ဆုံးနဲ့အမြစ်ပြတ်ပျောက်ကင်းမယ်ဆိုတာလဲနောက်မှဆက်ရေးပေးပါမယ်။အခုတော့နားလိုက်ပါဦးမယ်။
Kelvin Albert Power
(Nutrition Specialist, Florida, USA)
———————-
*********References************
1. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2:262–265. [PubMed] [Google Scholar]
2. Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther. 2005;22 Suppl 2:24–27. [PubMed] [Google Scholar]
3. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–1218. [PubMed] [Google Scholar]
4. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113–119. [PubMed] [Google Scholar]
5. Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, Shah SR, Rathi PM, Joshi AS, Thakkar H, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009;57:205–210. [PubMed] [Google Scholar]
6. Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011;31:700–706. [PubMed] [Google Scholar]
7. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42:132–138. [PubMed] [Google Scholar]
8. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873. [PubMed] [Google Scholar]
9. Porepa L, Ray JG, Sanchez-Romeu P, Booth GL. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ. 2010;182:E526–E531. [PMC free article] [PubMed] [Google Scholar]
10. Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol. 2001;96:2957–2961. [PubMed] [Google Scholar]
11. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617–649. [PubMed] [Google Scholar]
12. Amarapurka DN, Amarapurkar AD, Patel ND, Agal S, Baigal R, Gupte P, Pramanik S. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Ann Hepatol. 2006;5:30–33. [PubMed] [Google Scholar]
13. Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004;19:854–858. [PubMed] [Google Scholar]
14. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434–438. [PubMed] [Google Scholar]
15. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–1419. [PubMed] [Google Scholar]
16. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–2474. [PubMed] [Google Scholar]
17. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321. [PubMed] [Google Scholar]
18. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231. [PubMed] [Google Scholar]
19. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, Saveria Crocè L, Sasso F, Pozzato G, Cristianini G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997;41:845–850. [PMC free article] [PubMed] [Google Scholar]
20. Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22:775–777. [PubMed] [Google Scholar]
21. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–S112. [PubMed] [Google Scholar]
22. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395. [PubMed] [Google Scholar]
23. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686–690. [PubMed] [Google Scholar]
24. Fan JG. [An introduction of strategies for the management of nonalcoholic fatty liver disease (NAFLD) recommended by Asia Pacific Working Party on NAFLD] Zhonghua Gan Zang Bing Zazhi. 2007;15:552–553. [PubMed] [Google Scholar]
25. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28:155–161. [PubMed] [Google Scholar]
26. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131. [PubMed] [Google Scholar]
27. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249–1253. [PubMed] [Google Scholar]
28. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121. [PubMed] [Google Scholar]
29. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, Shiratori K. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44 Suppl 19:89–95. [PubMed] [Google Scholar]
30. McGill M, Molyneaux L, Twigg SM, Yue DK. The metabolic syndrome in type 1 diabetes: does it exist and does it matter? J Diabetes Complications. 2008;22:18–23. [PubMed] [Google Scholar]
31. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I, Sorgato C, Zenari L, Bonora E. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol. 2010;53:713–718. [PubMed] [Google Scholar]
32. Lv WS, Sun RX, Gao YY, Wen JP, Pan RF, Li L, Wang J, Xian YX, Cao CX, Zheng M. Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes. World J Gastroenterol. 2013;19:3134–3142. [PMC free article] [PubMed] [Google Scholar]
33. Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI, Reynolds RM, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34:1139–1144. [PMC free article] [PubMed] [Google Scholar]
34. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234–238. [PubMed] [Google Scholar]
35. Ratziu V, Bugianesi E, Dixon J, Fassio E, Ekstedt M, Charlotte F, Kechagias S, Poynard T, Olsson R. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment Pharmacol Ther. 2007;26:821–830. [PubMed] [Google Scholar]
36. Boza C, Riquelme A, Ibañez L, Duarte I, Norero E, Viviani P, Soza A, Fernandez JI, Raddatz A, Guzman S, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005;15:1148–1153. [PubMed] [Google Scholar]
37. Lima ML, Mourão SC, Diniz MT, Leite VH. Hepatic histopathology of patients with morbid obesity submitted to gastric bypass. Obes Surg. 2005;15:661–669. [PubMed] [Google Scholar]
38. Kemmer NM, Xiao SY, Singh H, Murray R, Abdo B. High prevalence of NASH among Mexican American females with type II diabetes mellitus. Gastroenterology. 2001;120 Suppl 1:A117 [abstract]. [Google Scholar]
39. Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Cornér A, Bergholm R, Yki-Järvinen H. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care. 2008;31:165–169. [PubMed] [Google Scholar]
40. Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56:943–951. [PMC free article] [PubMed] [Google Scholar]
41. Targher G, Chonchol M, Pichiri I, Zoppini G. Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence? J Endocrinol Invest. 2011;34:544–551. [PubMed] [Google Scholar]
42. Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010;5:2166–2171. [PMC free article] [PubMed] [Google Scholar]
43. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J Hepatol. 2011;54:1020–1029. [PubMed] [Google Scholar]
44. Targher G, Bertolini L, Chonchol M, Rodella S, Zoppini G, Lippi G, Zenari L, Bonora E. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia. 2010;53:1341–1348. [PubMed] [Google Scholar]
45. Lee YJ, Shim JY, Moon BS, Shin YH, Jung DH, Lee JH, Lee HR. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57:196–203. [PubMed] [Google Scholar]
46. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–854. [PubMed] [Google Scholar]
47. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–1447. [PubMed] [Google Scholar]
48. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51:371–379. [PubMed] [Google Scholar]
49. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48:634–642. [PubMed] [Google Scholar]
50. Ryysy L, Häkkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Järvinen H. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes. 2000;49:749–758. [PubMed] [Google Scholar]
51. Manchanayake J, Chitturi S, Nolan C, Farrell GC. Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2011;26:510–516. [PubMed] [Google Scholar]
52. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, Hirschhorn JN, O’Donnell CJ, Fox CS. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology. 2010;51:1979–1987. [PMC free article] [PubMed] [Google Scholar]
53. Targher G, Byrne CD. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98:483–495. [PubMed] [Google Scholar]
54. Kasturiratne A, Weerasinghe S, Dassanayake AS, Rajindrajith S, de Silva AP, Kato N, Wickremasinghe AR, de Silva HJ. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol. 2013;28:142–147. [PubMed] [Google Scholar]
55. Choi JH, Rhee EJ, Bae JC, Park SE, Park CY, Cho YK, Oh KW, Park SW, Lee WY. Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study. Arch Med Res. 2013;44:115–120. [PubMed] [Google Scholar]
56. Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, Park SW, Kim SW. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care. 2011;34:727–729. [PMC free article] [PubMed] [Google Scholar]
57. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711–725.e6. [PubMed] [Google Scholar]
58. Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, Finch J, Gastaldelli A, Harrison S, Tio F, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012;55:1389–1397. [PubMed] [Google Scholar]
59. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147–152. [PMC free article] [PubMed] [Google Scholar]
60. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343–1351. [PMC free article] [PubMed] [Google Scholar]
61. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology. 2002;35:898–904. [PubMed] [Google Scholar]
62. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52:774–788. [PubMed] [Google Scholar]
63. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183–1192. [PubMed] [Google Scholar]
64. Brenner DA, Seki E, Taura K, Kisseleva T, Deminicis S, Iwaisako K, Inokuchi S, Schnabl B, Oesterreicher CH, Paik YH, et al. Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol Res. 2011;41:683–686. [PMC free article] [PubMed] [Google Scholar]
65. Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab. 2003;285:E906–E916. [PubMed] [Google Scholar]
66. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011;60:313–326. [PubMed] [Google Scholar]
67. Leite NC, Salles GF, Cardoso CR, Villela-Nogueira CA. Serum biomarkers in type 2 diabetic patients with non-alcoholic steatohepatitis and advanced fibrosis. Hepatol Res. 2013;43:508–515. [PubMed] [Google Scholar]
68. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46–54. [PubMed] [Google Scholar]
69. Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD) Prog Lipid Res. 2009;48:1–26. [PubMed] [Google Scholar]
70. Cuoco L, Montalto M, Jorizzo RA, Santarelli L, Arancio F, Cammarota G, Gasbarrini G. Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics. Hepatogastroenterology. 2002;49:1582–1586. [PubMed] [Google Scholar]
71. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:1461–1465. [PMC free article] [PubMed] [Google Scholar]
72. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53:1883–1894. [PubMed] [Google Scholar]
73. Speliotes EK, Butler JL, Palmer CD, Voight BF, Hirschhorn JN. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 2010;52:904–912. [PMC free article] [PubMed] [Google Scholar]
74. Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP, et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J Hepatol. 2012;56:448–454. [PubMed] [Google Scholar]
75. Rubin D, Helwig U, Pfeuffer M, Schreiber S, Boeing H, Fisher E, Pfeiffer A, Freitag-Wolf S, Foelsch UR, Doering F, et al. A common functional exon polymorphism in the microsomal triglyceride transfer protein gene is associated with type 2 diabetes, impaired glucose metabolism and insulin levels. J Hum Genet. 2006;51:567–574. [PubMed] [Google Scholar]
76. Osman KA, Osman MM, Ahmed MH. Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going? Expert Opin Drug Saf. 2007;6:1–4. [PubMed] [Google Scholar]
77. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis. 2002;22:185–194. [PubMed] [Google Scholar]
78. Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S. ASH and NASH. Dig Dis. 2011;29:202–210. [PubMed] [Google Scholar]
79. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, Sterling RK, Shiffman ML, Stravitz RT, Sanyal AJ. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–1292. [PubMed] [Google Scholar]
80. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology. 2005;42:650–656. [PubMed] [Google Scholar]
81. Chandok N, Minuk G, Wengiel M, Uhanova J. Serum ferritin levels do not predict the stage of underlying non-alcoholic fatty liver disease. J Gastrointestin Liver Dis. 2012;21:53–58. [PubMed] [Google Scholar]
82. Vuppalanchi R, Gould RJ, Wilson LA, Unalp-Arida A, Cummings OW, Chalasani N, Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int. 2011:May 10; Epub ahead of print. [PMC free article] [PubMed] [Google Scholar]
83. Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol. 2007;23:193–198. [PubMed] [Google Scholar]
84. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med. 2007;24:1–6. [PubMed] [Google Scholar]
85. Targher G, Byrne CD. Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. Semin Thromb Hemost. 2013;39:214–228. [PubMed] [Google Scholar]
86. Younossi Z, Matteoni C, Gramlich T, Boparai N, Price L, McCullough A. Diabetes and non-alcoholic fatty liver disease: A worrisome combination. Gastroenterology. 1999;116:A1292 [abstract]. [Google Scholar]
87. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104–1112. [PMC free article] [PubMed] [Google Scholar]
88. Wieckowska A, Feldstein AE. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis. 2008;28:386–395. [PubMed] [Google Scholar]
89. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis. 2001;21:71–80. [PubMed] [Google Scholar]
90. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–750. [PubMed] [Google Scholar]
91. Debongnie JC, Pauls C, Fievez M, Wibin E. Prospective evaluation of the diagnostic accuracy of liver ultrasonography. Gut. 1981;22:130–135. [PMC free article] [PubMed] [Google Scholar]
92. Foster KJ, Dewbury KC, Griffith AH, Wright R. The accuracy of ultrasound in the detection of fatty infiltration of the liver. Br J Radiol. 1980;53:440–442. [PubMed] [Google Scholar]
93. Ballestri S, Lonardo A, Romagnoli D, Carulli L, Losi L, Day CP, Loria P. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. Liver Int. 2012;32:1242–1252. [PubMed] [Google Scholar]
94. Limanond P, Raman SS, Lassman C, Sayre J, Ghobrial RM, Busuttil RW, Saab S, Lu DS. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. Radiology. 2004;230:276–280. [PubMed] [Google Scholar]
95. van Werven JR, Marsman HA, Nederveen AJ, Smits NJ, ten Kate FJ, van Gulik TM, Stoker J. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology. 2010;256:159–168. [PubMed] [Google Scholar]
96. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology. 2011;259:749–756. [PMC free article] [PubMed] [Google Scholar]
97. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51:433–445. [PubMed] [Google Scholar]
98. Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol. 2013;10:666–675. [PubMed] [Google Scholar]
99. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, Sandrin L, Miette V. Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825–1835. [PubMed] [Google Scholar]
100. de Lédinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32:911–918. [PubMed] [Google Scholar]
101. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, Kowo M, Chan AW, Merrouche W, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454–462. [PubMed] [Google Scholar]
102. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59:1265–1269. [PubMed] [Google Scholar]
103. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–1362. [PubMed] [Google Scholar]
104. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6. [PMC free article] [PubMed] [Google Scholar]
105. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, Kaye P, Burt AD, Ryder SD, Aithal GP, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008;47:455–460. [PubMed] [Google Scholar]
106. Chen J, Zhu Y, Zheng Q, Jiang J. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: A meta-analysis. Hepatol Res. 2013:Jul 9; Epub ahead of print. [PubMed] [Google Scholar]
107. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–1609. [PubMed] [Google Scholar]
108. Bellentani S, Dalle Grave R, Suppini A, Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology. 2008;47:746–754. [PubMed] [Google Scholar]
109. Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology. 2008;48:119–128. [PubMed] [Google Scholar]
110. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885–904. [PubMed] [Google Scholar]
111. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011;106:460–48; quiz 469. [PMC free article] [PubMed] [Google Scholar]
112. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, Day CP, Trenell MI. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60:1278–1283. [PMC free article] [PubMed] [Google Scholar]
113. Bacchi E, Negri C, Targher G, Faccioli N, Lanza M, Zoppini G, Zanolin E, Schena F, Bonora E, Moghetti P. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial) Hepatology. 2013;58:1287–1295. [PubMed] [Google Scholar]
114. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, Pigeyre M, Verkindt H, Dharancy S, Louvet A, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137:532–540. [PubMed] [Google Scholar]
115. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6:1396–1402. [PubMed] [Google Scholar]
116. Parker HM, Johnson NA, Burdon CA, Cohn JS, O’Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;56:944–951. [PubMed] [Google Scholar]
117. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011;106:71–77. [PubMed] [Google Scholar]
118. Athyros VG, Tziomalos K, Daskalopoulos GN, Karagiannis A, Mikhailidis DP. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med. 2011;43:167–171. [PubMed] [Google Scholar]
119. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770–778. [PubMed] [Google Scholar]
120. Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, Zeuzem S, Hein J, Berg T. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:472–479. [PubMed] [Google Scholar]
121. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004;19:537–544. [PubMed] [Google Scholar]
122. Haukeland JW, Konopski Z, Eggesbø HB, von Volkmann HL, Raschpichler G, Bjøro K, Haaland T, Løberg EM, Birkeland K. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol. 2009;44:853–860. [PubMed] [Google Scholar]
123. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The Effect of Metformin and Standard Therapy versus Standard Therapy alone in Nondiabetic Patients with Insulin Resistance and Nonalcoholic Steatohepatitis (NASH): A Pilot Trial. Therap Adv Gastroenterol. 2009;2:157–163. [PMC free article] [PubMed] [Google Scholar]
124. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010;116:1938–1946. [PMC free article] [PubMed] [Google Scholar]
125. Lai SW, Chen PC, Liao KF, Muo CH, Lin CC, Sung FC. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol. 2012;107:46–52. [PubMed] [Google Scholar]
126. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, Borg B, Loomba R, Liang TJ, Premkumar A, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 2007;46:424–429. [PubMed] [Google Scholar]
127. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297–2307. [PubMed] [Google Scholar]
128. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1176–1184. [PubMed] [Google Scholar]
129. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685. [PMC free article] [PubMed] [Google Scholar]
130. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care. 1999;22:288–293. [PubMed] [Google Scholar]
131. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11:115–128. [PubMed] [Google Scholar]
132. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP, Vaughn DJ, Nessel L, Selby J, Strom BL. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34:916–922. [PMC free article] [PubMed] [Google Scholar]
133. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R, Fishman S. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol. 2011;54:1214–1223. [PubMed] [Google Scholar]
134. Svegliati-Baroni G, Saccomanno S, Rychlicki C, Agostinelli L, De Minicis S, Candelaresi C, Faraci G, Pacetti D, Vivarelli M, Nicolini D, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011;31:1285–1297. [PubMed] [Google Scholar]
135. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771. [PMC free article] [PubMed] [Google Scholar]
136. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46. [PubMed] [Google Scholar]
137. Cariou B, Hanf R, Lambert-Porcheron S, Zaïr Y, Sauvinet V, Noël B, Flet L, Vidal H, Staels B, Laville M. Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care. 2013;36:2923–2930. [PMC free article] [PubMed] [Google Scholar]
138. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574–82.e1. [PubMed] [Google Scholar]